M61.19
Myositis ossificans progressiva, multiple sites
Clinical Classification Guidelines
Medical Intelligence & Overview
Myositis ossificans progressiva, also known as Fibrodysplasia ossificans progressiva (FOP), is a rare, genetic disorder characterized by the abnormal development of bone in muscles, tendons, ligaments, and other connective tissues. Over time, this extra bone formation can lead to significant physical disability, restricting movement and causing deformities. Because of its progressive nature, early diagnosis and management are essential to help improve quality of life for affected individuals.
Causes & Symptoms
Clinical Causes: Genetic mutation in the ACVR1 gene, which affects bone growth regulation. Inheritance in an autosomal dominant pattern, meaning only one copy of the mutated gene can cause the disorder. In rare cases, the condition can occur due to new mutations without a family history.
Key Symptoms: Gradual formation of bone in soft tissues at multiple sites, often following injury or trauma. Swelling, warmth, or lumps in affected muscles or connective tissues. Restricted movement due to ossification around joints, leading to stiffness and deformity. Progressive ossification that leads to spinal deformities and limited mobility. Physical deformities, such as malformed big toes present from birth, which can be a diagnostic clue.
Diagnostic & Treatment
Diagnosis Path: Diagnosis of myositis ossificans progressiva is primarily based on clinical examination and medical history. Healthcare providers may use the following methods:
Treatment Protocols: Currently, there is no cure for myositis ossificans progressiva. Management focuses on alleviating symptoms, preventing complications, and maintaining mobility:
Clinical Advice & FAQs
Billing Guidance
Is M61.19 a billable ICD-10 code?
Yes, M61.19 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report M61.19?
Clinical documentation must specify the nature of Myositis ossificans progressiva, multiple sites and any associated comorbidities for accurate reporting.
Cite this Clinical Reference